Skip to content

A clinical trial to study the glucose level in the blood through Glysure continuous intravascular glucose monitoring device in patients admitted to ICUs

Initial Assessment of Precision and Bias for GlySure Continuous Intravascular Glucose Monitoring System

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2010/091/000480
Enrollment
90
Registered
2010-06-02
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Post surgical patients admitted into ICUs and expected to remain in ICU for 2-4 days

Interventions

Intervention1: Medical device: Control Intervention1: laboratory blood glucose analyser: Control Intervention2: i-STAT 1 Analyser MN:300: Model Number: i-STAT 1 MN:300

Sponsors

GlySure Ltd
Lead Sponsor
JSS Medical Research India Ltd
Collaborator

Eligibility

Inclusion criteria

Inclusion criteria: 1.Patient is admitted to the Intensive Care Unit (ICU) and is expected to remain in the ICU for at least 24 hours. 2. The patient must be able to be catheterised with the selected catheter. 3. The patient is aged 18 or over. 4. The patient or legal representative has given Informed consent in writing.

Exclusion criteria

Exclusion criteria: 1. You are aged under 18. 2. You are pregnant. 3. You have occlusive vascular disease. 4. You have undergone recent prior cannulation at the site chosen for cannulation for the study. 5. You have a history of embolism or thrombosis. 6. You have severe haemorrhagic diathesis. 7. You have presence of local sepsis. 8. You have history of heparin induced thrombocytopenia. 9. You are participating in another study that could affect the outcome.

Design outcomes

Primary

MeasureTime frame
1.Demonstrate acceptability of performance of system, with attention to precision and bias, as compared with the i-STAT Blood Glucose Analyser 2.Demonstrate that precision and bias is acceptable in either arterial or venous placement. 3.Quantify change in precision and bias over average patientâ??s length of stay in the ICU. 4.Identify potential interferences relating to patient disease states or therapy. 5.To determine which sensor membrane offers optimum results Timepoint: 7 days

Secondary

MeasureTime frame
1.To determine the system meets the userâ??s needs and in particular its ease of use/handling 2. To determine any specific user instructions necessary. 3. To characterise the type and severity of complications associated with the use of the device and therefore any additional warnings and cautions necessary that have not already been identified.Timepoint: 7 days

Countries

India

Contacts

Public ContactDr Shariq Anwar

Care Hospitals

palepu_gopal@hotmail.com919000361678

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026